AGL 38.15 Decreased By ▼ -1.43 (-3.61%)
AIRLINK 125.07 Decreased By ▼ -6.15 (-4.69%)
BOP 6.85 Increased By ▲ 0.04 (0.59%)
CNERGY 4.45 Decreased By ▼ -0.26 (-5.52%)
DCL 7.91 Decreased By ▼ -0.53 (-6.28%)
DFML 37.34 Decreased By ▼ -4.13 (-9.96%)
DGKC 77.77 Decreased By ▼ -4.32 (-5.26%)
FCCL 30.58 Decreased By ▼ -2.52 (-7.61%)
FFBL 68.86 Decreased By ▼ -4.01 (-5.5%)
FFL 11.86 Decreased By ▼ -0.40 (-3.26%)
HUBC 104.50 Decreased By ▼ -6.24 (-5.63%)
HUMNL 13.49 Decreased By ▼ -1.02 (-7.03%)
KEL 4.65 Decreased By ▼ -0.54 (-10.4%)
KOSM 7.17 Decreased By ▼ -0.44 (-5.78%)
MLCF 36.44 Decreased By ▼ -2.46 (-6.32%)
NBP 65.92 Increased By ▲ 1.91 (2.98%)
OGDC 179.53 Decreased By ▼ -13.29 (-6.89%)
PAEL 24.43 Decreased By ▼ -1.25 (-4.87%)
PIBTL 7.15 Decreased By ▼ -0.19 (-2.59%)
PPL 143.70 Decreased By ▼ -10.37 (-6.73%)
PRL 24.32 Decreased By ▼ -1.51 (-5.85%)
PTC 16.40 Decreased By ▼ -1.41 (-7.92%)
SEARL 78.57 Decreased By ▼ -3.73 (-4.53%)
TELE 7.22 Decreased By ▼ -0.54 (-6.96%)
TOMCL 31.97 Decreased By ▼ -1.49 (-4.45%)
TPLP 8.13 Decreased By ▼ -0.36 (-4.24%)
TREET 16.13 Decreased By ▼ -0.49 (-2.95%)
TRG 54.66 Decreased By ▼ -2.74 (-4.77%)
UNITY 27.50 Decreased By ▼ -0.01 (-0.04%)
WTL 1.29 Decreased By ▼ -0.08 (-5.84%)
BR100 10,089 Decreased By -415.2 (-3.95%)
BR30 29,509 Decreased By -1717.6 (-5.5%)
KSE100 94,574 Decreased By -3505.6 (-3.57%)
KSE30 29,445 Decreased By -1113.9 (-3.65%)

The government's move to introduce Drug Regulatory Authority (DRA) would bring Pakistan's pharmaceutical sector into a new pricing regime where drug prices would be controlled by the manufacturers instead of the regulators.
This information was given in a press conference arranged by The Network for Consumer Protection, a civil society advocacy group working in public health and consumer protection for the last 14 years, at a press conference, here on Friday.
Tauqeer Mustafa said that a detailed analysis of the proposed DRA Act and framework of the new regulatory authority gives maximum yet totally undue and unjustified leeway to the manufacturers in pricing.
"The drugs are distributed in five categories and separate mechanisms for price control would be working. With the exception of WHO's essential drugs list, all other four categories are left almost unregulated and at the industry's behalf. The self-certification for pricing and third party certification for quality is what the authority's draft is offering, it simply means that quality drugs would be sold at higher prices and availability of essential drugs (direly needed in Pakistan) to all and sundry would not be ensured", he elaborated.
Tauqir while questioning the move to establish new authority termed the action aimed at introducing a new authority as unnecessary and a bid to divert the attention of people from real issues of health sector.
"The loopholes in the framework of the authority show that the new body would privatise the pharmaceutical regulation in the country," he added. The draft of proposed body revealed that the new authority is being devised on the lines that it would result in further mess in terms of further price hike in the chaotic pharmaceutical sector.

Copyright Business Recorder, 2006

Comments

Comments are closed.